Ublituximab
Evidence-based neurology checklist on ublituximab: Pharmacology Ublituximab is a glycoengineered anti-CD20 monoclonal antibody It depletes B cells by antibody-dependent cellular cytotoxicity Pharmacology Dosing Precautions Adverse events
Pharmacology
- Ublituximab is a glycoengineered anti-CD20 monoclonal antibody
- It depletes B cells by antibody-dependent cellular cytotoxicity
Pharmacology
Dosing
Precautions
Adverse events
References
- Lee A. Ublituximab: first approval. Drugs 2023; 83:455-459.
- Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021; 27:420-429.
- Mukhtar H, Yasmeen U, Siddiqa S, Sarfraz Z, Sarfraz A. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: a meta-analysis. Mult Scler Relat Disord 2022; 65:104002.
